ArticleBlood2008
Screening for hemochromatosis by measuring ferritin levels: a more effective approach.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review.The Brown journal of hospital medicine · 2022Pooled it
- EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).European journal of human genetics : EJHG · 2016Guideline
- Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.Human molecular genetics · 2011Pooled it
- Prevalence of metabolic hyperferritinemia and association between ferritin and insulin resistance in persons with impaired glucose regulation in the HUNT2 population study.Diabetology & metabolic syndrome · 2026Article
- Predictors of mortality, mortality rates, and clinical characteristics of adult patients with extreme hyperferritinemia.Irish journal of medical science · 2024Article
- Minimizing Contact Resistance and Flicker Noise in Micro Graphene Hall Sensors Using Persistent Carbene Modified Gold Electrodes.ACS applied materials & interfaces · 2024Article
- Beyond the Usual Suspects: Hereditary Hemochromatosis and Transaminitis in Primary Care.Cureus · 2023Article
- Hematoxylin Nuclear Stain Reports Oxidative Stress via Near-Infrared Emission.ACS chemical biology · 2023Article
- A Mystery of Joint Pain: Is It Rheumatoid Arthritis (RA) or Hereditary Hemochromatosis (HH)?Cureus · 2022Article
- A Minimal Parameter Set Facilitating Early Decision-making in the Diagnosis of Hemophagocytic Lymphohistiocytosis.Journal of clinical immunology · 2021Article
- Article
- Article
- Hyperferritinemia-A Clinical Overview.Journal of clinical medicine · 2021Review
- Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report.World journal of clinical cases · 2020Article
- Use of C-Reactive Protein and Ferritin Biomarkers in Daily Pediatric Practice.Pediatrics in review · 2020Review
- Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Review
- Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Molecular medicine (Cambridge, Mass.) · 2018Review
- High Neonatal Blood Iron Content Is Associated with the Risk of Childhood Type 1 Diabetes Mellitus.Nutrients · 2017Article
- Article
- Iron status and survival in diabetic patients with coronary artery disease.Diabetes care · 2013Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Because the penetrance of HFE hemochromatosis is low, traditional population screening measuring the transferrin saturation is unlikely to be cost-effective because the majority of subjects detected neither have clinical disease nor are likely to develop it. Three independent studies show that only patients with serum ferritin concentrations more than 1000 microg/L are at risk for cirrhosis, one of the main morbidities of hemochromatosis. Among 29,699 white subjects participating in the Scripps/Kaiser hemochromatosis study, only 59 had serum ferritin levels more than 1000 microg/L; 24 had homozygous mutant or compound heterozygous mutant HFE genotypes. In all but 5 of the other subjects, the causes of elevated ferritin were excessive alcohol intake, cancer, or liver disease. Screening for hemochromatosis with serum ferritin levels will detect the majority of patients who will be clinically affected and may detect other clinically significant disease in patients who do not have hemochromatosis genotypes. Because the ferritin level of the majority of adult homozygotes for HFE mutations does not rise over long periods of time, excluding subjects with serum ferritin levels less than or equal to 1000 microg/L should not result in missed opportunities for early treatment of patients who could benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.